Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M.E. Lacouture, L.M. Reilly, P. Gerami, J. Guitart.
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Ann Oncol, 19 (2008), pp. 1955-1961
[2.]
C. Robert, J.C. Soria, A. Spatz, A. Le Cesne, D. Malka, P. Pautier, et al.
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Lancet Oncol, 6 (2005), pp. 491-500
[3.]
S.E. Rosenbaum, S. Wu, M.A. Newman, D.P. West, T. Kuzel, M.E. Lacouture.
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
Support Care Cancer, 16 (2008), pp. 557-566
[4.]
N. Heidary, H. Naik, S. Burgin.
Chemotherapeutic agents and the skin: An update.
J Am Acad Dermatol, 58 (2008), pp. 545-570
[5.]
L.Q. Chow, S.G. Eckhardt.
Sunitinib: from rational design to clinical efficacy.
J Clin Oncol, 25 (2007), pp. 884-896
[6.]
W.J. Lee, J.L. Lee, S.E. Chang, M.W. Lee, Y.K. Kang, J.H. Choi, et al.
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Br J Dermatol, 161 (2009), pp. 1045-1051
[7.]
A. Martorell-Calatayud, C. Requena, E. Nagore-Enguídanos, C. Guillén-Barona.
Úlceras dolorosas múltiples en la pierna resistentes al tratamiento asociadas a lesiones “dermatomiositislike” en las articulaciones interfalángicas de las manos inducidas por hidroxiurea.
Actas Dermosifiliogr, 100 (2009), pp. 804-807
Copyright © 2011. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
